According to the principle of patient autonomy, patients have the right to be self-determining in decisions about their own medical care, which includes the right to refuse treatment. However, a treatment refusal may legitimately be overridden in cases where the decision is judged to be incompetent. It has recently been proposed that in assessments of competence, attention should be paid to the evaluative judgments that guide patients’ treatment decisions. In this paper I examine this claim in light of theories of practical rationality, focusing on the difficult case of an …

Recently, Julian Savulescu and Guy Kahane have defended the Principle of Procreative Beneficence (PB), according to which prospective parents ought to select children with the view that their future child has ‘the best chance of the best life’. I argue that the arguments Savulescu and Kahane adduce in favour of PB equally well support what I call the Principle of General Procreative Beneficence (GPB). GPB states that couples ought to select children in view of maximizing the overall expected value in the world, not just the welfare of their future …

Makers of SpaCapsule Sign 250 Capsule Deal With Major French Concern, Securing a Four Year Revenue Stream — Strengthening Global Appeal

Makers of SpaCapsule Sign 250 Capsule Deal With Major French Concern, Securing a Four Year Revenue Stream — Strengthening Global Appeal

Makers of SpaCapsule Sign 250 Capsule Deal With Major French Concern, Securing a Four Year Revenue Stream — Strengthening Global Appeal

MISSISSAUGA, ON–(Marketwire – December 30, 2009) – (PINKSHEETS: HRAL) HearAtLast Holdings,
Inc., a leading provider of suitable affordable solutions to clients with
hearing needs in the billion dollar hearing loss market, today announced
that Canadian Business Journal recently interviewed Robert J. Oswald,
Executive Vice President of HearAtLast Holdings, on the future of
HearAtLast and the Canadian Hearing Health Care Market.

MISSISSAUGA, ON–(Marketwire – December 30, 2009) – (PINKSHEETS: HRAL) HearAtLast Holdings,
Inc., a leading provider of suitable affordable solutions to clients with
hearing needs in the billion dollar hearing loss market, today announced
that Canadian Business Journal recently interviewed Robert J. Oswald,
Executive Vice President of HearAtLast Holdings, on the future of
HearAtLast and the Canadian Hearing Health Care Market.

MISSISSAUGA, ON–(Marketwire – December 30, 2009) – (PINKSHEETS: HRAL) HearAtLast Holdings,
Inc., a leading provider of suitable affordable solutions to clients with
hearing needs in the billion dollar hearing loss market, today announced
that Canadian Business Journal recently interviewed Robert J. Oswald,
Executive Vice President of HearAtLast Holdings, on the future of
HearAtLast and the Canadian Hearing Health Care Market.

QUEBEC, CANADA–(Marketwire – Dec. 30, 2009) – Victhom Human Bionics Inc. (“Victhom” or the “Company”) (TSX:VHB) announced today that concurrent to voluntary delisting from the Toronto Stock Exchange, the common shares of the Company will commence trading on the TSX Venture Exchange effective at the opening of trading on December 31, 2009. The Company will be classified as a Tier 1 Technology Issuer on the TSX Venture Exchange. The Company’s common shares trading symbol, “VHB”, and their CUSIP number, 92581Q502, will remain unchanged.

QUEBEC, CANADA–(Marketwire – Dec. 30, 2009) – Victhom Human Bionics Inc. (“Victhom” or the “Company”) (TSX:VHB) announced today that concurrent to voluntary delisting from the Toronto Stock Exchange, the common shares of the Company will commence trading on the TSX Venture Exchange effective at the opening of trading on December 31, 2009. The Company will be classified as a Tier 1 Technology Issuer on the TSX Venture Exchange. The Company’s common shares trading symbol, “VHB”, and their CUSIP number, 92581Q502, will remain unchanged.